- Home
- CRIS vs NXTS Comparison
CRIS vs NXTS Comparison
Compare CRIS & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRIS | NXTS |
|---|---|---|
| Founded | 2000 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 2.1M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CRIS | NXTS |
|---|---|---|
| Price | $0.64 | $0.77 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $42.67 | N/A |
| AVG Volume (30 Days) | ★ 160.7K | 150.7K |
| Earning Date | 11-05-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.57 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,898,000.00 | $263,445.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 31.50 | N/A |
| 52 Week Low | $0.34 | $0.82 |
| 52 Week High | $3,360.00 | $53.90 |
Technical Indicators
Market Signals| Indicator | CRIS | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 19.38 | 20.61 |
| Support Level | $0.34 | N/A |
| Resistance Level | $5.50 | $2.08 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | 1.34 | -0.05 |
| Stochastic Oscillator | 6.85 | 1.71 |
Price Performance
Historical ComparisonAbout CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About NXTS Nexentis Technologies Inc. Common Stock
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.